A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.
Mark James McKeage
Consultant or Advisory Role - OncoMed (U)
Dusan Kotasek
No relevant relationships to disclose
Ben Markman
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose
Michael Millward
No relevant relationships to disclose
Michael B. Jameson
No relevant relationships to disclose
Dean Laurence Harris
No relevant relationships to disclose
Robert J. Stagg
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Jakob Dupont
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Brett Gordon Maxwell Hughes
No relevant relationships to disclose